Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
BPC-157 is a synthetic 15-amino-acid peptide studied mainly in cells and animal models. Public interest is far ahead of robust human clinical evidence.
Key points
- The compound is a synthetic pentadecapeptide described in the literature as a fragment associated with a gastric protein called body protection compound.
- Evidence from cells, animals and humans must be interpreted separately.
- Investigational and not authorised by the MHRA as a medicine. WADA lists BPC-157 among prohibited non-approved substances in sport.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
BPC-157 is a synthetic 15-amino-acid peptide studied mainly in cells and animal models. Public interest is far ahead of robust human clinical evidence. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
Published experiments have explored fibroblast migration, nitric-oxide-related signalling, angiogenesis and responses to experimental injury. No single validated mechanism explains the broad claims commonly made online.
What does the current evidence show?
- Cell and animal studies report effects in tendon, gastrointestinal, vascular and inflammatory models.
- A tendon-fibroblast study reported changes in cell survival and migration in vitro.
- Recent reviews conclude that human evidence remains extremely limited, with no completed Phase 2 programme or validated pharmaceutical formulation.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Animal injury models cannot establish healing effects in humans.
- Human pharmacokinetics, dose-response relationships and long-term safety remain inadequately characterised.
- Online claims often combine unrelated preclinical outcomes and omit negative or uncertain evidence.
Regulatory and safety context
Investigational and not authorised by the MHRA as a medicine. WADA lists BPC-157 among prohibited non-approved substances in sport. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.